Francesca Caldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca Caldi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Farese
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
1 shared publication - Alessandro Bartoloni
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
1 shared publication - Elisa Muz
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
1 shared publication - Francesca Mangani
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
1 shared publication - Gian Maria Rossolini
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
1 shared publication - Lorenzo Corbetta
Department of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 63, 50134 Florence, Italy
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (3) , 863-875
Rapid testing with molecular syndromic panels of patients presenting at the emergency department with pneumonia at risk for multidrug-resistant pathogens
Background: Pneumonia remains a major cause of morbidity and mortality worldwide. Rapid diagnostic testing with molecular syndromic panels (MSP) has proved useful for the management of antimicrobial treatment of hospital-acquired pneumonia (HAP). In this study, we evaluated the impact of early use of MSP testing in the Emergency Department (ED) for the management of antibiotic therapy in patients with moderate to severe CAP with risk factors for multi-drug-resistant pathogens (CAP-MDR). Patients and methods: Patients presenting at the ED with diagnosis of moderate to severe CAP-MDR underwent microbiological analysis of lower respiratory tract specimens by culture and MSP testing (bioMérieux, FilmArray ® Pneumonia Plus Panel). The primary outcome was the percentage of cases in which MSP testing modified the empiric antimicrobial therapy started according to local protocols. Among the secondary outcomes we included the time elapsed from ED admission to antibiotic change or confirmation upon receipt of the MSP results. Results: Between June 2024 and May 2025, 93 patients were enrolled (age, 72.9 ± 13.9 years; 62.4% males). MSP testing identified one or more pathogens in 91.4% of cases. Modification of empiric antibiotic therapy, started according to local protocols, occurred in 65.6% of patients (escalation in 44.1% and de-escalation in 21.5% of cases) after 11.4 ± 6.3 h (IQR 12.0) since ED presentation. Conclusions: The early use of MSP on lower respiratory samples collected in the ED from patients with diagnosis of moderate to severe CAP-MDR could allow a rapid and targeted modification of the empiric antibiotic therapy in these patients, with potential advantages on antimicrobial stewardship and patient management.
- 10 December 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (3) , 863-875
Open AccessRapid testing with molecular syndromic panels of patients presenting at the emergency department with pneumonia at risk for multidrug-resistant pathogens
Background: Pneumonia remains a major cause of morbidity and mortality worldwide. Rapid diagnostic testing with molecular syndromic panels (MSP) has proved useful for the management of antimicrobial treatment of hospital-acquired pneumonia (HAP). In this study, we evaluated the impact of early use of MSP testing in the Emergency Department (ED) for the management of antibiotic therapy in patients with moderate to severe CAP with risk factors for multi-drug-resistant pathogens (CAP-MDR). Patients and methods: Patients presenting at the ED with diagnosis of moderate to severe CAP-MDR underwent microbiological analysis of lower respiratory tract specimens by culture and MSP testing (bioMérieux, FilmArray ® Pneumonia Plus Panel). The primary outcome was the percentage of cases in which MSP testing modified the empiric antimicrobial therapy started according to local protocols. Among the secondary outcomes we included the time elapsed from ED admission to antibiotic change or confirmation upon receipt of the MSP results. Results: Between June 2024 and May 2025, 93 patients were enrolled (age, 72.9 ± 13.9 years; 62.4% males). MSP testing identified one or more pathogens in 91.4% of cases. Modification of empiric antibiotic therapy, started according to local protocols, occurred in 65.6% of patients (escalation in 44.1% and de-escalation in 21.5% of cases) after 11.4 ± 6.3 h (IQR 12.0) since ED presentation. Conclusions: The early use of MSP on lower respiratory samples collected in the ED from patients with diagnosis of moderate to severe CAP-MDR could allow a rapid and targeted modification of the empiric antibiotic therapy in these patients, with potential advantages on antimicrobial stewardship and patient management.